269 related articles for article (PubMed ID: 18802063)
1. T cells from Leishmania major-susceptible BALB/c mice have a defect in efficiently up-regulating CXCR3 upon activation.
Barbi J; Brombacher F; Satoskar AR
J Immunol; 2008 Oct; 181(7):4613-20. PubMed ID: 18802063
[TBL] [Abstract][Full Text] [Related]
2. Transgenic expression of CXCR3 on T cells enhances susceptibility to cutaneous Leishmania major infection by inhibiting monocyte maturation and promoting a Th2 response.
Oghumu S; Stock JC; Varikuti S; Dong R; Terrazas C; Edwards JA; Rappleye CA; Holovatyk A; Sharpe A; Satoskar AR
Infect Immun; 2015 Jan; 83(1):67-76. PubMed ID: 25312956
[TBL] [Abstract][Full Text] [Related]
3. CXCR3-/- mice mount an efficient Th1 response but fail to control Leishmania major infection.
Rosas LE; Barbi J; Lu B; Fujiwara Y; Gerard C; Sanders VM; Satoskar AR
Eur J Immunol; 2005 Feb; 35(2):515-23. PubMed ID: 15668916
[TBL] [Abstract][Full Text] [Related]
4. BALB/c mice bearing a transgenic IL-12 receptor beta 2 gene exhibit a nonhealing phenotype to Leishmania major infection despite intact IL-12 signaling.
Nishikomori R; Gurunathan S; Nishikomori K; Strober W
J Immunol; 2001 Jun; 166(11):6776-83. PubMed ID: 11359836
[TBL] [Abstract][Full Text] [Related]
5. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response.
Mattner F; Magram J; Ferrante J; Launois P; Di Padova K; Behin R; Gately MK; Louis JA; Alber G
Eur J Immunol; 1996 Jul; 26(7):1553-9. PubMed ID: 8766560
[TBL] [Abstract][Full Text] [Related]
6. IL-7 receptor expression provides the potential for long-term survival of both CD62Lhigh central memory T cells and Th1 effector cells during Leishmania major infection.
Colpitts SL; Dalton NM; Scott P
J Immunol; 2009 May; 182(9):5702-11. PubMed ID: 19380817
[TBL] [Abstract][Full Text] [Related]
7. Depletion of peritoneal CD5+ B cells has no effect on the course of Leishmania major infection in susceptible and resistant mice.
Babai B; Louzir H; Cazenave PA; Dellagi K
Clin Exp Immunol; 1999 Jul; 117(1):123-9. PubMed ID: 10403925
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility to Leishmania major in IL-4 transgenic mice is not correlated with the lack of a Th1 immune response.
Erb KJ; Blank C; Moll H
Immunol Cell Biol; 1996 Jun; 74(3):239-44. PubMed ID: 8799723
[TBL] [Abstract][Full Text] [Related]
9. The early IL-4 response to Leishmania major and the resulting Th2 cell maturation steering progressive disease in BALB/c mice are subject to the control of regulatory CD4+CD25+ T cells.
Aseffa A; Gumy A; Launois P; MacDonald HR; Louis JA; Tacchini-Cottier F
J Immunol; 2002 Sep; 169(6):3232-41. PubMed ID: 12218142
[TBL] [Abstract][Full Text] [Related]
10. Leishmania major-infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis.
von Stebut E; Belkaid Y; Nguyen BV; Cushing M; Sacks DL; Udey MC
Eur J Immunol; 2000 Dec; 30(12):3498-506. PubMed ID: 11093169
[TBL] [Abstract][Full Text] [Related]
11. T cell-derived IL-10 determines leishmaniasis disease outcome and is suppressed by a dendritic cell based vaccine.
Schwarz T; Remer KA; Nahrendorf W; Masic A; Siewe L; Müller W; Roers A; Moll H
PLoS Pathog; 2013; 9(6):e1003476. PubMed ID: 23825956
[TBL] [Abstract][Full Text] [Related]
12. Despite increased CD4+Foxp3+ cells within the infection site, BALB/c IL-4 receptor-deficient mice reveal CD4+Foxp3-negative T cells as a source of IL-10 in Leishmania major susceptibility.
Nagase H; Jones KM; Anderson CF; Noben-Trauth N
J Immunol; 2007 Aug; 179(4):2435-44. PubMed ID: 17675505
[TBL] [Abstract][Full Text] [Related]
13. IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice.
Lopez Kostka S; Dinges S; Griewank K; Iwakura Y; Udey MC; von Stebut E
J Immunol; 2009 Mar; 182(5):3039-46. PubMed ID: 19234200
[TBL] [Abstract][Full Text] [Related]
14. STAT1 expression in dendritic cells, but not T cells, is required for immunity to Leishmania major.
Johnson LM; Scott P
J Immunol; 2007 Jun; 178(11):7259-66. PubMed ID: 17513775
[TBL] [Abstract][Full Text] [Related]
15. CD28 costimulation and parasite dose combine to influence the susceptibility of BALB/c mice to infection with Leishmania major.
Compton HL; Farrell JP
J Immunol; 2002 Feb; 168(3):1302-8. PubMed ID: 11801669
[TBL] [Abstract][Full Text] [Related]
16. IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection.
Jones DE; Buxbaum LU; Scott P
J Immunol; 2000 Jul; 165(1):364-72. PubMed ID: 10861073
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice.
Gessner A; Blum H; Röllinghoff M
Immunobiology; 1993 Dec; 189(5):419-35. PubMed ID: 8125519
[TBL] [Abstract][Full Text] [Related]
18. JNK1 is required for T cell-mediated immunity against Leishmania major infection.
Constant SL; Dong C; Yang DD; Wysk M; Davis RJ; Flavell RA
J Immunol; 2000 Sep; 165(5):2671-6. PubMed ID: 10946297
[TBL] [Abstract][Full Text] [Related]
19. NF-kappa B1 is required for optimal CD4+ Th1 cell development and resistance to Leishmania major.
Artis D; Speirs K; Joyce K; Goldschmidt M; Caamaño J; Hunter CA; Scott P
J Immunol; 2003 Feb; 170(4):1995-2003. PubMed ID: 12574369
[TBL] [Abstract][Full Text] [Related]
20. Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response.
Muraille E; De Trez C; Brait M; De Baetselier P; Leo O; Carlier Y
J Immunol; 2003 Apr; 170(8):4237-41. PubMed ID: 12682257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
